Status:
COMPLETED
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
Lead Sponsor:
Pfizer
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF...
Eligibility Criteria
Inclusion
- Mild to moderate Alzheimer's disease (MMSE 14-26)
- Good general health (such controlled conditions as Type 2 diabetes and hypertension allowed)
Exclusion
- Use of acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or memantine within 12 weeks of the start of the study
- Significant cardiovascular disease in the past 6 months
- Illness other than Alzheimer's disease that could contribute to cognitive impairment
- History of stroke or seizure disorder
Key Trial Info
Start Date :
September 10 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 22 2010
Estimated Enrollment :
191 Patients enrolled
Trial Details
Trial ID
NCT00930059
Start Date
September 10 2009
End Date
September 22 2010
Last Update
November 19 2020
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurology Clinic, PC
Northport, Alabama, United States, 35476
2
ATP Clinical Research, Inc.
Costa Mesa, California, United States, 92626
3
Southwestern Research Incorporated
Glendale, California, United States, 91204
4
Pacific Coast Imaging (for Imaging only)
Newport Beach, California, United States, 92663